Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

AtriCure's Frustratingly Slow Build Hides Value Beneath

Many investors like to believe that all a med-tech company has to do is develop a product for an under-served market, secure FDA approval, and then sit back and count the money as it rolls in. If only it were so easy. Marketing is often overlooked as a primary challenge, as new therapies often require doctors to change their routines and practices and may threaten older, profitable ways of doing business.

That seems particularly relevant in the case of AtriCure (NASDAQ:ATRC). While AtriCure has a good suite of products to treat atrial fibrillation, uptake has been slow and the company is still below the $100 million barrier in annual revenue. Although it's going to take time and patience...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details